The FDA cleared the company’s OCD motor threshold (MT) cap technology for NeuroStar advanced therapy for mental health.
According to a news release, determining a patient’s MT represents a critical step to establishing their prescription before starting treatment. NeuroStar, a transcranial magnetic stimulation (TMS) system, holds FDA clearance for MT caps for both OCD and major depressive disorder.
The MT cap simplifies the initial NeuroStar placement, Neuronetics says. It provides a consistent starting location and a step-by-step process to map a patient’s motor cortex. This effectively shortens the time needed and reduces the number of steps involved in the process.
Neuronetics said its MT cap features compatibility with Fast MT, providing up to 40% time savings for clinicians and patients in the initial visit.
The company said nearly 300 patients with OCD already received treatment with NeuroStar TMS. Neuronetics plans to make its OCD MT cap available at select sites this month. The company expects nationwide availability to come in the fourth quarter of this year.
“This FDA clearance underscores our commitment to delivering the latest technology that will streamline the treatment process for our customers,” said Cory Anderson, SVP of R&D and clinical at Neuronetics. “The unique design and functionality of the OCD MT Cap will enable clinicians to optimize treatment efficiency while upholding the highest standard of care for their patients. This innovation also prepares NeuroStar for even further technological advancements expected later this year and next.”
